Etomethazene

Etomethazene (5-methyldesnitroetonitazene, 5-methyl etodesnitazene, Eto) is a benzimidazole derivative with opioid effects which has been sold as a designer drug over the internet since 2022, first being definitively identified in Sweden in January 2023.^[1][2] It is an analogue of etonitazene where the nitro (NO₂) group has been replaced by a methyl (CH₃) group. While formal studies into its pharmacology have yet to be carried out, it showed far less potency than etonitazene itself. Etomethazene has an analgesic potency around 20 times that of morphine with a relatively short duration of about 120 min.^[3][4][5]

Etomethazene

Identifiers
IUPAC name 2-[(4-ethoxyphenyl)methyl]-N,N-diethyl-5-methyl-1H-benzimidazole-1-ethanamine
CAS Number	95293-25-7
PubChem CID	168310446
Chemical and physical data
Formula	C23H31N3O
Molar mass	365.521 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCOc3ccc(Cc2nc1cc(C)ccc1n2CCN(CC)CC)cc3
InChI InChI=1S/C23H31N3O/c1-5-25(6-2)14-15-26-22-13-8-18(4)16-21(22)24-23(26)17-19-9-11-20(12-10-19)27-7-3/h8-13,16H,5-7,14-15,17H2,1-4H3 Key:ZARKNPABJGEAOQ-UHFFFAOYSA-N

See also

• Etoacetazene
• Etocyanazene
• Etodesnitazene
• Etonitazepyne
• Isotonitazene
• Metonitazene
• List of benzimidazole opioids